X-ray Crystal Structure of Phosphodiesterase 2 in Complex with a Highly Selective, Nanomolar Inhibitor Reveals a Binding-Induced Pocket Important for Selectivity

被引:58
作者
Zhu, Jian [1 ,2 ]
Yang, Qjqi [1 ]
Dai, Dandan [1 ]
Huang, Qiang [1 ]
机构
[1] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China
[2] Shanghai Medicilon Inc, Shanghai 201299, Peoples R China
关键词
SUBSTRATE-SPECIFICITY; OBJECT MEMORY; MECHANISM; TARGETS; TYPE-2; MODEL; CGMP;
D O I
10.1021/ja404449g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To better understand the structural origins of inhibitor selectivity of human phosphodieasterase families (PDEs 1-11), here we report the X-ray crystal structure of PDE2 in complex with a highly selective, nanomolar inhibitor (BAY60-7550) at 1.9 angstrom resolution, and the structure of apo PDE2 at 2.0 angstrom resolution. The crystal structures reveal that the inhibitor binds to the PDE2 active site by using not only the conserved glutamine-switch mechanism for substrate binding, but also a binding-induced, hydrophobic pocket that was not reported previously. In silico affinity profiling by molecular docking indicates that the inhibitor binding to this pocket contributes significantly to the binding affinity and thereby improves the inhibitor selectivity for PDE2. Our results highlight a structure-based design strategy that exploits the potential binding-induced pockets to achieve higher selectivity in the PDE inhibitor development.
引用
收藏
页码:11708 / 11711
页数:4
相关论文
共 21 条
[1]   Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use [J].
Bender, Andrew T. ;
Beavo, Joseph A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :488-520
[2]   Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance [J].
Boess, FG ;
Hendrix, M ;
van der Staay, FJ ;
Erb, C ;
Schreiber, R ;
van Staveren, W ;
de Vente, J ;
Prickaerts, J ;
Blokland, A ;
Koenig, G .
NEUROPHARMACOLOGY, 2004, 47 (07) :1081-1092
[3]   Structural basis for the activity of drugs that inhibit phosphodiesterases [J].
Card, GL ;
England, BP ;
Suzuki, Y ;
Fong, D ;
Powell, B ;
Lee, B ;
Luu, C ;
Tabrizizad, M ;
Gillette, S ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
STRUCTURE, 2004, 12 (12) :2233-2247
[4]   ROSETTALIGAND Docking with Full Ligand and Receptor Flexibility [J].
Davis, Ian W. ;
Baker, David .
JOURNAL OF MOLECULAR BIOLOGY, 2009, 385 (02) :381-392
[5]   The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging [J].
Domek-Lopacinska, K. ;
Strosznajder, J. B. .
BRAIN RESEARCH, 2008, 1216 :68-77
[6]   Roflumilast [J].
Fabbri, Leonardo M. ;
Beghe, Bianca ;
Yasothan, Uma ;
Kirkpatrick, Peter .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :761-762
[7]   Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity [J].
Ke, Hengming ;
Wang, Huanchen .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (04) :391-403
[8]   Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments [J].
Keravis, Therese ;
Lugnier, Claire .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (05) :1288-1305
[9]  
LaVallie ER, 2000, METHOD ENZYMOL, V326, P322
[10]   Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice [J].
Masood, Anbrin ;
Nadeem, Ahmed ;
Mustafa, S. Jamal ;
O'Donnell, James M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (02) :369-379